Displaying drugs 10276 - 10300 of 12433 in total
Cenderitide
Cenderitide is under investigation for the treatment of ST Elevation (STEMI) Myocardial Infarction of Anterior Wall.
Investigational
Matched Description: … Cenderitide is under investigation for the treatment of ST Elevation (STEMI) Myocardial Infarction of …
Suvratoxumab
Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
Investigational
Matched Description: … Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of …
DS-2325a
DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.
Investigational
Matched Description: … DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome. …
Nifekalant
Nifekalant is under investigation in clinical trial NCT03855826 (Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection).
Investigational
Matched Description: … of Nifekalant Hydrochloride (NIF) Injection). ... Nifekalant is under investigation in clinical trial NCT03855826 (Evaluation of the Efficacy and Safety …
XmAb 2513
XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been investigated for the treatment of hodgkin’s lymphoma.
Investigational
Matched Description: … a number of tumor cell types. ... It has been investigated for the treatment of hodgkin’s lymphoma. ... a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of …
SYNB1020
SYNB1020 is an engineered strain of Escherichia coli Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016; however, the manufacturer discontinued further development of SYNB1020 to treat...
Investigational
Matched Description: … SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 ... SYNB1020 is an engineered strain of _Escherichia coli_ Nissle 1917 developed by Synlogic Inc. ... convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of …
Menaquinone 6
Menaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different Dosages Vitamin K2).
Investigational
Matched Description: … Menaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different …
BLX-883
BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide sales currently exceed $3 billion.
Investigational
Matched Description: … BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. ... Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide …
Baicalein
Baicalein is under investigation in clinical trial NCT03830684 (A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever).
Investigational
Matched Description: … Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever). ... Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of …
Gatralimab
Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment).
Investigational
Matched Description: … Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml ... Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial …
PN0621
PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
Investigational
Fibrinolysin
Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. Fibrinolysin is used as a...
Investigational
Matched Description: … The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin ... ; the heavy chain has a molecular weight of approximately 57,000 Da. ... Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. …
Dianexin
Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients).
Investigational
Matched Description: … Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin …
Terevalefim
Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational
Matched Description: … of a Deceased Donor Kidney). ... Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients …
Etavopivat
Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.
Investigational
Matched Description: … the treatment of sickle cell disease. ... Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for …
UV1
UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments of the hTERT subunit
Investigational
Matched Description: … of the hTERT subunit ... UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments …
Varlitinib
Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.
Investigational
Matched Description: … Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients ... Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 ... Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and …
PTI-801
PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone. It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.
Investigational
Matched Description: … PTI-801 represents a new class of drugs to treat pain. ... It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. ... can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of …
PF-05241328
PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity).
Investigational
Matched Description: … Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not ... under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of …
Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was developed using domains of viral structural proteins and a polyprotein protease. Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these...
Investigational
Matched Description: … Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was ... developed using domains of viral structural proteins and a polyprotein protease. ... Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, …
Afimoxifene
Afimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia. TamoGel is formulated using Enhanced Hydroalcoholic Gel (EHG) Technology. This technology enables percutaneous delivery of drugs that cannot be delivered orally. It is being developed by...
Investigational
Matched Description: … This technology enables percutaneous delivery of drugs that cannot be delivered orally. ... Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of …
Fucoxanthin
Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. Fucoxanthin is investigated for its anti-inflammatory, antinociceptive and anti-cancer effects....
Investigational
Matched Description: … action of fucoxanthin is not fully elucidated. ... an animal model of duodenal, skin, colon and liver cancer. ... of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). …
Pegamotecan
Pegamotecan has been used in trials studying the treatment of Cancer of Stomach, Sarcoma, Soft Tissue, and Gastroesophageal Cancer.
Investigational
Matched Description: … Pegamotecan has been used in trials studying the treatment of Cancer of Stomach, Sarcoma, Soft Tissue …
Aganirsen
Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG).
Investigational
Matched Description: … at Risk of Developing NVG). ... Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients …
BacTRL-spike
BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. The vaccine was developed by Symvivo Corporation. As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to...
Investigational
Matched Description: … BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum ... Trial (NCT04334980) to test the safety and immunogenicity of the vaccine. ... As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled …
Displaying drugs 10276 - 10300 of 12433 in total